NCT06018623

Brief Summary

Patients who will be anesthesia induced with propofol will be body analyzed with Tanita before the operation. Height, weight, age, gender and other general information of the patients will be recorded. Total body weight (TBW), ideal body weight (IBW) and lean body weight (LBW) will be calculated. Patients over 18 years of age who will be operated under general anesthesia for 2-6 hours will be included. Patients allergic to propofol or contraindicated to propofol will be excluded. In the study, in order to decide and test the most appropriate weight-based scale for the evaluation of propofol dosage for induction of anesthesia by identifying patients who need additional propofol during intubation, Ingrande et al. After monitoring, propofol infusion (100 mg/kg/hour) will be started according to total body weight and the infusion will be stopped when the BIS value is between 50 and 40 and the elapsed time will be recorded. Routine anesthesia applications will be performed by applying neuromuscular blocker. Total Propofol dose administered will be calculated according to the dose TBW, IBW and LBW in kilograms. The relationship between the doses administered and body mass index will be evaluated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2023

Completed
21 days until next milestone

First Posted

Study publicly available on registry

August 30, 2023

Completed
9 months until next milestone

Study Start

First participant enrolled

May 15, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 15, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2024

Completed
Last Updated

March 7, 2024

Status Verified

March 1, 2024

Enrollment Period

5 months

First QC Date

August 9, 2023

Last Update Submit

March 5, 2024

Conditions

GenderAnesthesia

Keywords

the lean body weight, propofol intubation conditions

Outcome Measures

Primary Outcomes (1)

  • PROPOFOL DOSE

    THE RATIO OF PROPOFOL DOSE WITH SUFFICIENT DEPTH OF ANESTHESIA ACCORDING TO TOTAL AND LEATHER BODY WEIGHT

    2

Study Arms (3)

grup 1.Optimum range

Group 1 BMI = 18.5-24.9,

Other: It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients

Group 2.Overweight

BMI = 25-29.9,

Other: It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients

Group 3.Class I obesity

BMI=30-34.9

Other: It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients

Interventions

It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patientsOTHER

It is an observational study and no non-routine procedures will be performed on patients. Routine anesthesia procedure will be applied to the patients

Group 2.OverweightGroup 3.Class I obesitygrup 1.Optimum range

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

VOLUNTARY PATIENTS BETWEEN 18-65 YEARS WITH NO ADDITIONAL DISEASES

You may not qualify if:

  • PATIENT DOESN'T WANT CONTRAINDICATION OF PROPOFOL Propofol allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Inonu universitesi

Malatya, 44050, Turkey (Türkiye)

Location

Related Publications (2)

  • Barras M, Legg A. Drug dosing in obese adults. Aust Prescr. 2017 Oct;40(5):189-193. doi: 10.18773/austprescr.2017.053. Epub 2017 Oct 3. No abstract available.

    PMID: 29109603BACKGROUND

  • Fujimoto M, Tanahira C, Nishi M, Yamamoto T. In non-obese patients, duration of action of rocuronium is directly correlated with body mass index. Can J Anaesth. 2013 Jun;60(6):552-6. doi: 10.1007/s12630-013-9914-x. Epub 2013 Mar 6.

    PMID: 23463483BACKGROUND

Related Links

MeSH Terms

Conditions

Coitus

Condition Hierarchy (Ancestors)

Sexual BehaviorBehavior

Central Study Contacts

duygu demiroz, dr

CONTACT

905319504421drduygudemiroz@hotmail.com

yusuf ziya colak, dr

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr

Study Record Dates

First Submitted

August 9, 2023

First Posted

August 30, 2023

Study Start

May 15, 2024

Primary Completion

October 15, 2024

Study Completion

November 30, 2024

Last Updated

March 7, 2024

Record last verified: 2024-03

Locations

TU(1)